- Accueil >
- Publications >
- Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
Auteurs
Philippe Rousselot, Marie Magdelaine Coudé, Nicola Gokbuget, Carlo Gambacorti Passerini, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, Thibaut Leguay, Patrice Chevallier, Celia Salanoubat, Caroline Bonmati, Magda Alexis, Mathilde Hunault, Sylvie Glaisner, Philippe Agape, Christian Berthou, Eric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumedaly Reman, Bruno Lioure, Xavier Thomas, Norbert Ifrah, Marina Lafage-Pochitaloff, Anne Bornand, Laure Morisset, Valérie Robin, Heike Pfeifer, Andre Delannoy, Josep Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Herve Dombret, Oliver G. Ottmann
Résumé
Key Points
Dasatinib, combined with low-intensity chemotherapy, gave 36% 5-year overall survival in Ph+ ALL patients older than age 55 years. Prospective monitoring of mutations may be useful to personalize therapy in Ph+ ALL patients not eligible for intensive therapies.